EyePoint, Equinox enter licensing agreement for vorolanib

EyePoint Pharmaceuticals and Equinox Science have signed an exclusive license agreement for the development of vorolanib, according to a press release.

Vorolanib, a tyrosine kinase inhibitor, is being developed as EYP-1901 for the treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion using EyePoint’s bioerodible Durasert technology.

“EyePoint is dedicated to developing and commercializing innovative treatments for ocular diseases, and we are very excited about the potential for EYP-1901 as a vital, new 6-month treatment for serious eye diseases, including wet AMD, DR and RVO,” Nancy Lurker, president and CEO of EyePoint, said in the release. “We are encouraged by the potential of vorolanib, as it demonstrated a promising phase 1 and phase 2 efficacy signal in prior human [wet] AMD studies as an oral therapy and in preclinical animal studies as intravitreal EYP-1901. Our proven Durasert technology provides the unique opportunity to investigate EYP-1901 as a 6-month treatment option for patients that also has the potential to avoid the frequent injections required for currently available biologics.”

Under the agreement, EyePoint will develop and commercialize vorolanib across the world, excluding China, Macau, Hong Kong and Taiwan. The company will make a $1 million upfront payment to Equinox Science and pay developmental and regulatory milestones and commercial royalties, the release said.

EyePoint Pharmaceuticals and Equinox Science have signed an exclusive license agreement for the development of vorolanib, according to a press release.

Vorolanib, a tyrosine kinase inhibitor, is being developed as EYP-1901 for the treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion using EyePoint’s bioerodible Durasert technology.

“EyePoint is dedicated to developing and commercializing innovative treatments for ocular diseases, and we are very excited about the potential for EYP-1901 as a vital, new 6-month treatment for serious eye diseases, including wet AMD, DR and RVO,” Nancy Lurker, president and CEO of EyePoint, said in the release. “We are encouraged by the potential of vorolanib, as it demonstrated a promising phase 1 and phase 2 efficacy signal in prior human [wet] AMD studies as an oral therapy and in preclinical animal studies as intravitreal EYP-1901. Our proven Durasert technology provides the unique opportunity to investigate EYP-1901 as a 6-month treatment option for patients that also has the potential to avoid the frequent injections required for currently available biologics.”

Under the agreement, EyePoint will develop and commercialize vorolanib across the world, excluding China, Macau, Hong Kong and Taiwan. The company will make a $1 million upfront payment to Equinox Science and pay developmental and regulatory milestones and commercial royalties, the release said.